Skip to content
Dx

ICD-10-PCS 2027 procedure code

XW013TBIntroduction of Rozanolixizumab-noli Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 11

✓ Valid for 2027

Short description: Introduce Rozanolixizumab in Subcu, Perc, New Tech 11

Code last changed in FY2026 (effective October 1, 2025). Source: official FY2027 ICD-10-PCS release from CMS. Page updated September 29, 2026. About our data

About XW013TB

XW013TB is the ICD-10-PCS code for a introduction procedure on the subcutaneous tissue using a percutaneous approach with rozanolixizumab-noli monoclonal antibody (qualifier: new technology group 11). In ICD-10-PCS, introduction means putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products.

It doesn't appear in the MS-DRG procedure index, so on its own it doesn't change the DRG assignment.

It was added in FY2026, effective October 1, 2025.

What each character means

1. Section
XNew Technology
2. Body System
WAnatomical Regions
3. Operation
0Introduction

Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products

4. Body Part
1Subcutaneous Tissue
5. Approach
3Percutaneous

Entry, by puncture or minor incision, of instrumentation through the skin or mucous membrane and any other body layers necessary to reach the site of the procedure

6. Device / Substance / Technology
TRozanolixizumab-noli Monoclonal Antibody

Includes: RYSTIGGO(R)

7. Qualifier
BNew Technology Group 11

Other versions of this procedure

Code history

  1. 2016
  2. 2017
  3. 2018
  4. 2019
  5. 2020
  6. 2021
  7. 2022
  8. 2023
  9. 2024
  10. 2025
  11. 2026
  12. 2027
  • FY2026 (effective 10/1/2025): Added
  • No changes since FY2026.

Common questions about XW013TB

Is XW013TB a valid ICD-10-PCS code for 2027?

Yes. XW013TB is valid for inpatient procedures from October 1, 2026 through September 30, 2027.